IL3RA and acute myeloid leukemia: IL3RA-ADC administered at 10 mg/kg inhibited the growth of IL3RA-positive AML cells, as indicated by temporarily reduced numbers of hCD45-positive cells in blood compared to vehicle or isotype control ADC in both settings (Figure 3C,D; all p < 0.001).